News Bayer’s Stivarga fast-tracked for liver cancer review Bayer’s cancer treatment Stivarga has been granted priority review status by the FDA for use as a second line treatment of unresectable hepatocellular carcinoma (uHCC).
News Bayer teams with Leica for personalised cancer tests Collaboration will create tools capable of improving cancer treatment choices.
News BeyondSpring plans three-pronged attack on cancer The CEO of BeyondSpring said the company hopes to make its name with a new lung cancer drug and an innovative R&D strategy.
News MSD and Bayer launch big gamble on heart failure candidate Aims to recruit 4,900 patients to prove value in heart failure
News NICE says no to liver cancer drug Nexavar Liver cancer treatment latest earmarked for removal from CDF
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.